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Abstract
Newborn screening aims at detecting treatable disorders
early so that the treatment can be initiated to prevent
mortality and morbidity. Such programmes are well
established in most developed countries, and all newborns
are screened for selected metabolic, endocrine and other
disorders based on disease epidemiology, testing and
treatment availability, eﬃciency and cost-eﬀectiveness.
Even in developing countries, such screening programmes
are initiated using heel prick capillary blood collected on
filter paper. The current narrative review was planned to
provide a perspective with evidence in favour of starting
newborn screening for diﬀerent disorders. The programme
project should be initiated nationwide, taking one disorder,
congenital hypothyroidism, as the prototype and a
newborn screening panel can then be extended to include
other disorders. A task force should be set up to
recommend disorders to be included in the panel, develop
the national plan policies, and define procedures to
strengthen the testing.
Keywords: Newborn screening, Pakistan, Congenital
hypothyroidism, Congenital adrenal hyperplasia,
Biotinidase deficiency, Galactosemia, Sickle cell disease,
Hemoglobinopathies.
DOI: https://doi.org/10.47391/JPMA.01181

Introduction
Newborn screening (NBS) for inherited diseases is a
secondary prevention strategy that involves evaluating
neonates within the first few days of life before the clinical
manifestation of the diseases screened.1 The aim is to
provide early diagnosis and to prevent or ameliorate longterm consequences from a treatable disorder.
NBS programmes have been an important public health
strategy for more than 50 years and have evolved
tremendously over the years in the developed world.2 It
1-3,6-8Department of Pathology and Laboratory Medicine, Aga Khan University,

Karachi, Pakistan; 4,5Department of Pediatrics and Child Health, Aga Khan
University, Karachi, Pakistan; 9Department of Pediatrics, Child Health,
Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
Correspondence: Aysha Habib Khan. Email: aysha.habib@aku.edu
Vol. 72, No. 3, March 2022

started from simple blood or urine screening test for
phenylketonuria (PKU) in 1963 by bacterial inhibition assay;
now, with the advent of ‘omics’, it is a more comprehensive
and complex screening system capable of detecting over
50 diﬀerent disorders.1 In 2006, the American College of
Medical Genetics (ACMG) recommended a screening panel
comprising 44 inherited metabolic disorders (IMDs)
(aminoacidopathies, fatty acid defects and organic
acidemias), two endocrinopathies, three haemoglobinopathies, hearing impairment and cystic fibrosis.3 The
majority of the conditions in the core panel and in
secondary targets require tandem mass spectrometry (MS)
as the main methodology, and others require
immunoassay and fluorometry.4
There has been increasing pressure to add more conditions
to NBS programmes, advancing omics. However,
establishing and expanding screening programmes is
challenging as many of these conditions are still not well
understood or treatable and have the potential to shift the
implications and uses of NBS. So, while establishing a NBS
programme, the first and foremost is to have a consensus
on conditions to be included in the programme .5
The W&J criterion developed in 1968 remains the gold
standard to select screening conditions, and several
adaptations have since emerged.6 The World Health
Organisation (WHO) in 2008 proposed some adaptations
of classic criteria, emphasising more on adequate
governance and regulatory framework, programme
eﬀectiveness, integrating education, testing clinical
services, programme management and evaluation from
the outset.5 The WHO also addresses quality assurance
issues by defining mechanisms for the target population
to minimise potential risks, ensuring informed choice,
confidentiality, respect for autonomy, promoting equity
and access to screening. The overall benefits of screening
should outweigh the harm.6 The conditions included in
NBS must be carefully evaluated based on medical and
scientific evidence surrounding the natural history of the
condition and the local ability to decrease morbidity and
mortality through screening.
The current narrative review was planned to present
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evidence for including congenital hypothyroidism (CH),
congenital adrenal hyperplasia (CAH), glucose 6
phosphatase dehydrogenase (G6PD) deficiency, sickle cell
disease (SCD), biotinidase deficiency (BTD) and
galactosemia for NBS in Pakistan. The data presented on
incidence is mostly from hospital-based studies.
Congenital hypothyroidism: CH is a serious disorder
aﬄicting neonates resulting in intellectual disability (ID) if
left undiagnosed and untreated. The worldwide incidence
of CH is around 1:2000-1:4000, while the estimated CH
incidence in Pakistan ranges from 1:1000 to 1:1600.7,8 Local
endemic iodine deficiency has been reported as a cause of
the higher incidence of CH in Pakistan.9
In the United States, every state has a diﬀerent core NBS
panel, but all the states screen for CH. In addition, CH is
included in the mandatory core NBS panel of all the
developed countries, while in many developing countries,
it is emerging as a priority. Some countries are performing
nationwide NBS for CH and certain other congenital and
metabolic disorders, whereas other countries oﬀer
screening to high-risk groups only. Most of these
programmes are supported by the government of the
respective countries.3,4
There is a need for a nationwide NBS programme for CH in
Pakistan. Primary CH screening is done by measuring
thyroid-stimulating hormone (TSH) on blood spot at 48-72
hours of age.10 Babies identified with high TSH on
screening should be seen within the next 24 to 48 hours
for clinical assessment and advised follow-up testing to
confirm CH. If TSH is ≥20mU/L and / or free thyroxin (FT4)
is below normal for age, treatment is initiated as early as
possible.10,11
Congenital adrenal hyperplasia: CAH is an autosomal
recessive (AR) inherited deficiency of enzymes involved in
adrenal steroidogenesis. The most common cause of CAH

is 21-hydroxylase enzyme deficiency (21-OHD), with an
overall incidence of 1:14000 live births, being equally
prevalent among both genders with variable phenotype.12
Globally, morbidity and mortality from CAH has
significantly reduced by the introduction of NBS for 21OHD. Added advantages of screening include decreasing
the time of gender assignment for babies born with
ambiguous genitalia, planning for puberty, avoiding the
development of precocious puberty and short stature in
the simple virilising forms. Furthermore, carrier detection
and genetic counselling for families having an aﬀected
child minimise the long-term complications for the
families.13
From a Pakistani perspective, the incidence reported by
scattered hospital-based studies is almost similar to global
studies, but has a relatively higher prevalence with late
diagnosis than the countries with an established NBS
programme.14 Moreover, alarmingly high numbers of CAH
cases, i.e. 53% and 82%, were reported from tertiary care
centres from Lahore and Karachi while evaluating children
with ambiguous genitalia and precocious puberty,
respectively.14,15 Additionally, our healthcare system lacks
clear policies on complex issues commonly seen in CAH,
such as ethical concerns and religious obligations in
legislation.16
Global experience of NBS with dried blood spot (DBS)
demonstrated reliability and eﬃciency for CAH testing.
Considering the availability of economical, eﬀective
treatment and the high number of cases of CAH reported
from Pakistan, now is the time for Pakistan to start NBS for
21-OHD. There is a dire need for advocacy and national
policy to cater to a suitably designed and organised
infrastructure for CAH NBS alongside genetic counselling
for aﬀected patients and families. Screening and
confirmatory tests available for NBS are shown in table
below.

Table: : Incidences of disorders which can be included in a newborn screening (NBS) panel for Pakistan.
S # Disorder

Screening Test

Diagnostic Test

Worldwide Incidence

Estimated Burden in Pakistan

1

Congenital Hypothyroidism

TSH on dried blood spot

Serum TSH and FT4

1:2000 to 4000 live births

1:1000-1600

2

Congenital Adrenal Hyperplasia

17 OHP on dried blood spot

Serum 17OHP, Synacthen
stimulation test and Molecular testing

1:14000 live births

1:5000

3

Biotinidase deficiency

Biotinidase enzyme activity
on dried blood spot

Plasma Biotinidase enzyme activity

1: 60000 to 109,921 live births 1:115 in patients suspected with
IMDs (unpublished data)

4

Galactossemia

Total Galactose or GALT enzyme Plasma GALT enzyme activity
activity on dried blood spot

1:40,000 to 60,000 live births Not known

5

Glucose 6 phosphate dehydro
genase deficiency

G6PD enzyme activity on
dried blood spot

1:350 to 700 live births

6

Sickle cell disease

Haemoglobin isoelectric focusing Haemoglobin HPLC (high performance 1: 500 to 16,300 live births
electrophoresis of an eluate from liquid chromatography)
the dried blood spots

Plasma G6PD activity Quantitative
analysis and molecular testing

4-14% of jaundiced infants
4% of the patients evaluated for
Anaemia or other blood related
disorders
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Glucose-6-phosphate dehydrogenase deficiency: G6PD
deficiency is an X-linked disorder aﬀecting about 400
million individuals around the globe.17 Neonates with
G6PD deficiency are susceptible to hyperbilirubinaemia
and acute bilirubin encephalopathy, kernicterus and even
death if untreated. The haemolytic crisis may occur later in
life when exposed to certain drugs and food. Neonatal
screening of jaundiced infants identified G6PD deficiency
in 4-14% of babies in two large hospitals in Pakistan.18-20
Unfortunately, up to 22% of them developed kernicterus
and 4% died. This makes a strong case for mass screening
of G6PD deficiency through biochemical testing. The
investigation is anticipated to identify all G6PD-deficient
males and homozygous females who may require
extended hospitalisation and monitoring. An additional
advantage would be an opportunity for parental education
for seeking medical care when required.
Sickle cell disease: SCD is the most common AR genetic
haematological disorder. The common genotypes include
sickle cell trait (HbAS) and sickle cell anaemia (HbSS).21 In
the US and Europe, all newborns are screened for SCD,
which helps identify carriers, subsequently leading to the
screening of females with positive family history, planning
for pregnancy.21,22
Shabbir et al. have reported a frequency of approximately
4% and 2% for SCD and HbAS, respectively, in Pakistan.23
In 2018, recommendations from a pan-European
consensus conference suggested NBS for SCD in all the
participating countries.22 Early detection and appropriate
management lead to improved quality of life and helps in
counselling to avoid risk factors that trigger painful crisis
and administration of prophylactic penicillin and
pneumococcal vaccine. NBS for SCD can be done by
targeted screening, restricted to “at risk” ethnic groups or
universal screening when the whole newborn population
is screened. The screening and diagnostic tests include
complete blood picture with peripheral smear,
haemoglobin (Hb) electrophoresis or high-performance
liquid chromatography (HPLC) and deoxyribonucleic acid
(DNA)-based tests to identify globin gene mutations.24
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commonest IMDs in Pakistan.26 Till to date, more than 150
patients suspected of BTD have been identified from the
biochemical genetics laboratory at the Aga Khan University
(AKU) on urine organic acid chromatography from across
Pakistan (unpublished data). Over ten years, 33 BTD cases
were confirmed using biotinidase assay and BTD gene
analysis.27 The BTD is an easily treatable IMD by a simple
and cheap oral supplementation of biotin, preventing
neurological deficit, hearing impairment and optic atrophy
and preventing life-threatening complications and death.
BTD is a strong candidate to be included in NBS in Pakistan
as sensitive and specific screening testing on DBS and
confirmatory BTD enzyme activity in plasma can be
developed.27,28
Galactosemia: Galactosemia is an AR inherited disorder that
results from a deficiency of any one of the three enzymes
catalysing the conversion of galactose to glucose:
galactose-1-phosphate
uridyltransferase
(GALT),
galactokinase (GALK), and uridine diphosphate galactose4-epimerase (GALE). The incidence of galactosemia
reported in the literature is about 1:53,554.29 The disorder
is not uncommon in Pakistan. A study from Pakistan
reported 22 patients with galactosemia out of the 239
patients suspected of IMDs.30 An accepted low-cost
treatment for patients with recognised galactossemia and
facilities for diagnosis and treatment can be made available
in Pakistan. Clear algorithms for diagnosis and
management of screening tests for galactossemia include
total galactose or GALT enzyme activity in DBS, whereas
enzyme activity testing and mutation analysis are the
confirmatory tests.31

Biotinidase deficiency: BTD is an AR inherited disorder
involving an enzymatic defect in the biotin cycle.25 Biotin
is a cofactor for four carboxylases involved in
gluconeogenesis, fatty acid synthesis and catabolism of
several branched-chain amino acids. Patients with BTD may
present with seizures, hypotonia, breathing problems,
hearing and vision loss, ataxia, skin rash and alopecia. If left
untreated, children with BTD will develop irreversible ID,
hearing impairment and optic atrophy.25

Why Pakistan Needs NBS? Pakistan has the highest
neonatal mortality rate with 44 per 1000 live births, and is
declared the most dangerous country for a baby to be
born. The causes of neonatal mortality reported in Pakistan
are sepsis, stillbirth, birth asphyxia, pneumonia and
seizures. The early neonatal presentation of IMDs are often
non-specific, symptoms mimicking sepsis-like illness or
birth asphyxia. Due to eﬀorts and intervention to reduce
birth asphyxia and sepsis by WHO and the government of
Pakistan, neonatal mortality has declined to 44.2 per 1000
live births from 51 per 1000 live births.32 In the absence of
NBS in Pakistan, these babies are not investigated; thus,
there is no data to provide information on how many
babies diagnosed with sepsis or birth asphyxia had an
underlying IMD. It has been demonstrated that the leading
cause of neonatal mortality in developed countries is noncommunicable diseases, including genetic disorders. It is
high time that NBS is implemented in Pakistan for selected
disorders.

A review of literature identifies BTD as one of the

NBS is a system; not a test: NBS is a complete system
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involving five essential components that are crucial for a
successful NBS system.33 They are as follows:
• Raising awareness and educating the public about the
importance and benefits of NBS. Acceptance of NBS by
the public is likely to be suboptimal without this essential
component.
• Targeting the expected new parents by imparting
education during the prenatal period through the
healthcare team involved in pregnancy and baby
delivery.
• Appropriate method of screening selected for the
particular group of disorders, e.g. heel prick for IMD,
haemoglobinopathies or endocrinopathies.
• A robust system to retrieve all babies with NBS-positive
results to confirm all NBS-positive results through a
confirmatory diagnostic test. Timely intervention
providing immediate and long-term evidence-based
quality treatment is essential for a complete NBS
programme.
• Outcome assessment of all NBS-positive babies and all
patients with true-positive results. Both the institute and
province/state are responsible for ensuring that regular
audits, lost to follow-up rates, developmental, physical,
and mental outcomes among the aﬀected children,
presence of ongoing evaluation of the eﬀectiveness of
various treatment protocols/regimens, evidence of use
of national standards to collect data and link systems are
implemented.
Recommendation for Pakistan: In the light of the discussion
above, we recommend including CH, CAH, BTD,
galactossaemia, G6PD and SCD in the screening panel for
Pakistan. The conditions included should not only fulfill the
W&J criterion, but must be carefully evaluated based on
medical and scientific evidence surrounding the natural
history of the condition and the local ability to decrease
morbidity and mortality through screening.1
Expanded NBS is performed in many developed countries
for the screening of amino acidopathies, including PKU,
maple syrup syndrome, fatty acid defects, like mediumchain acyl Co-enzyme A (CoA) dehydrogenase deficiency,
and organic acidemias, like methylmalonic academia.
However, introducing NBS for these disorders in Pakistan
at this stage without concrete evidence on prevalence is
not feasible due to the inequitable and limited availability
of screening and diagnostic testing, special milk formulae
or foods for special medical purpose, and lack of trained
personnel, including metabolic specialists. It is imperative
that a pilot NBS should be performed prior to
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recommending any of the IMDs for NBS. In addition, as per
the W&J criterion, only disorders that have appropriate,
cost-eﬀective treatments, sensitive, accurate screening and
diagnostic tests available should be included in a NBS
panel.1 Screening for another disorder that is prevalent in
Pakistan, but not recommended in this paper is
thalassemia. However, the best strategy for preventing
thalassemia major cases is a premarital screening of the
couple for thalassemia trait, rather than employing NBS.
Establishing NBS services requires collaboration between
laboratories,
pathologists,
nurses,
obstetricians,
paediatricians, physicians, parents/families and integration
of the systems for robust delivery of services. We
recommend establishing the NBS programme taking CH as
the prototype because of high incidence and cost-eﬀective
tests/treatments. Once the infrastructure is in place, the
programme can be expanded further to include other
disorders.
Care must be taken in introducing new diseases/
programmes not to make the same mistakes made by
others. Carefully planned pilot-testing should always
include a thorough analysis of public health impact and
cost-eﬀectiveness with an eye on the future. Developing
programmes must continually take advantage of progress
already made by others. Conditions and inherited disorders
are nominated and vetted to be included or excluded from
the NBS programme based on the burden, severity of the
condition, the availability of sensitive and specific
screening tests, including second-tier tests, and the
availability and eﬃcacy of treatment modalities.
Systemic approach to initiating NBS in Pakistan: We
recommend careful planning of NBS. This needs to start
with forming and NBS advisory committee, which should
include stakeholders from the government, including the
Ministry of Health, paediatricians, pathologists,
obstetricians, metabolic physicians representing both
private- and public-sector hospitals and involvement of
lady health workers in the community. Standard operating
procedures for each of the five critical components of the
NBS system described earlier will need to be developed.
Careful selection of disease to be included in the national
NBS panel will need to be decided. Access to treatment and
long-term follow-up become even more important issues
when NBS is expanded. It is important to avoid conditions
under which children who have undergone mandatory
screening are left with a diagnosis, but no resources and
means to treat their condition.33,34

Conclusion
The central idea of early disease detection and treatment
is essentially simple. However, the path to its achievement
J Pak Med Assoc
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(on the one hand, bringing to treatment those with the
previously undetected disease, and, on the other, avoiding
harm to those persons not in need of treatment) is far from
simple though sometimes it may appear deceptively easy.
It is important to highlight that screening does not cover
all inherited diseases and that diagnosis is presumptive, as
screening may yield false-negative or false-positive results.
A firm diagnosis can only be reached after confirmation.
Confirmatory testing can be done using the same
technology or diﬀerent approach on blood spot, urine and
plasma. All positive NBS results either need to be confirmed
or excluded after confirmatory testing.
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